Vijay Jayaprakash

Vijay Jayaprakash has extensive work experience in the field of clinical development and oncology. Vijay currently holds a position as the Vice President of Clinical Development at HUTCHMED, where they are responsible for overseeing early asset portfolio development, patient safety/pharmacovigilance, and non-clinical toxicology. Vijay leads the development program for small molecules inhibitors in lymphoma, leukemia, and solid tumors. Prior to this role, Vijay worked at Bristol Myers Squibb as a Development Program Leader and Clinical Development Lead, where they oversaw the strategy and trial conduct for various cancer treatments. Vijay also has experience working at AstraZeneca as a Medical Scientist and Medical Evidence Lead, as well as at the Roswell Park Comprehensive Cancer Center and University at Buffalo as a professor and research assistant professor, respectively.

Vijay Jayaprakash has pursued education in various fields related to health and medicine. At the University at Buffalo, they studied Epidemiology & Community Health. Vijay also attended Tamil Nadu Dr. M.G.R. Medical University in Chennai, where they focused on Medicine. Lastly, they pursued further education in Health Economics and Outcomes Research at the University of Washington. The specific start and end years for each program are not provided.